Halozyme Therapeutics (HALO) to Release Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is projected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Halozyme Therapeutics to post earnings of $1.17 per share and revenue of $285.74 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $57.34 on Tuesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a fifty-two week low of $34.36 and a fifty-two week high of $65.53. The stock has a fifty day moving average of $51.73 and a two-hundred day moving average of $54.42. The company has a market capitalization of $7.30 billion, a price-to-earnings ratio of 18.99, a PEG ratio of 0.44 and a beta of 1.25.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.